Windlas Biotech Limited (WINDLAS.BO) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2026-03-31. WINDLAS.BO files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.04% | 30.00% | Pass |
| Interest-bearing investments | 14.00% | 30.00% | Pass |
| Non-permissible income | 0.15% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.48% | 33.00% | Pass |
| Interest-bearing investments | 30.73% | 33.00% | Pass |
| Non-liquid assets | 44.21% | at least 20.00% | Pass |
| Non-permissible income | 0.15% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.48% | 33.33% | Pass |
| Cash + interest-bearing securities | 30.73% | 33.33% | Pass |
| Accounts receivable | 55.79% | 33.33% | Fail |
| Non-permissible income | 0.15% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.48% | 33.33% | Pass |
| Cash + interest-bearing securities | 30.73% | 33.33% | Pass |
| Accounts receivable | 55.79% | 50.00% | Fail |
| Non-permissible income | 0.15% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.61% | 33.00% | Pass |
| Cash + interest-bearing securities | 17.91% | 33.00% | Pass |
| Accounts receivable | 14.61% | 33.00% | Pass |
| Non-permissible income | 0.15% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.02% | 33.00% | Pass |
| Cash + interest-bearing securities | 20.75% | 49.00% | Pass |
| Accounts receivable | 16.93% | 49.00% | Pass |
| Non-permissible income | 0.15% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.02% | 33.33% | Pass |
| Cash + interest-bearing securities | 20.75% | 33.33% | Pass |
| Accounts receivable | 37.68% | 49.00% | Pass |
| Non-permissible income | 0.15% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 74.90 | SELL |
| Stochastic %K (14) | 81.13 | SELL |
| CCI (20) | 99.25 | NEUTRAL |
| Williams %R (14) | -18.87 | SELL |
| MACD (12,26,9) | 9.86 | BUY |
| ROC (10) | 15.67 | BUY |
| Momentum (10) | 154.00 | BUY |
| EMA (10) | 1095.64 | BUY |
| SMA (10) | 1090.55 | BUY |
| EMA (20) | 1043.31 | BUY |
| SMA (20) | 1029.83 | BUY |
| EMA (30) | 1006.66 | BUY |
| SMA (30) | 980.77 | BUY |
| EMA (50) | 959.50 | BUY |
| SMA (50) | 928.48 | BUY |
| EMA (100) | 903.53 | BUY |
| SMA (100) | 874.15 | BUY |
| EMA (200) | 868.92 | BUY |
| SMA (200) | 827.72 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. The company sells generic medicines, health supplements, and custom-branded formulations under Windlas brand names. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Background via Yahoo Finance — informational, not part of the verdict.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.